"Evidence for the efficacy of melatonin in the treatment of primary adult sleep disorders" (PDF)
This pattern suggests dose-dependent effects on metabolism or gastrointestinal side effects that lead to greater electrolyte and fluid losses
Post-mortem analysis of brains from patients with HD shows increased striatal and SNc DA and TH activity 3,4,5
(2000), Horm Res 53(Suppl 3), PubMed 10971106 Statistics from preclinical literature AOD-9604 = modified fragment of hGH 177191 + N-terminal Tyr (sequence Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe), molecular weight 1815.1 Da Developed at Metabolic Pharmaceuticals (Australia) based on the work of professor Frank Ng (Monash University) in the 1990s Standard experimental dose in obesity clinical trials: 1 mg/day subcutaneously (Phase 2b, Heffernan et al.) Mechanism: stimulation of 3-adrenergic receptors in adipose tissue, increased lipolysis and fatty acid oxidation without activation of the hGH receptor (no IGF-1 increase) Phase 2b clinical trial (2007, 300 patients): weight reduction ~2.8 kg vs placebo over 12 weeks FDA status: NDI rejection (2014) as a dietary supplement
Our attorneys counter this by comparing pre- and post-treatment imaging, gastric motility studies, and the drugs pharmacologic profile
Its important to differentiate between targeted herbal antimicrobials and broad-spectrum supplements that may not offer specific benefits for bacterial overgrowth